EFPIA Code of Practice on relationships between the pharmaceutical industry and patient organisations

Luc Hessel M.D.
European Vaccine Manufacturers
EFPIA: European Federation of Pharmaceutical Industries and Associations

• **Members**: 32 European national industry associations and 44 innovative pharmaceutical companies

• **Specialised Groups**:
  – European Vaccine Manufacturers
  – European Biopharmaceutical Enterprises

• **Primary mission**: to promote the technical and economic development of the pharmaceutical industry in Europe and to assist in bringing to market medicinal products which improve human health
Why working with patient groups?

• To better understand and address patient needs and concerns on research, medicines and medical interventions

• To support programmes that improve Public Health and lives of people with medical conditions

• To share priorities on access to medical interventions (prevention and cure) that best meet patients’ needs
Why working with patient groups: EVM perspective

• A new situation
  – vaccines are for healthy individuals
  – ... but not just for kids

• The general public plays an important role in the adoption of vaccination programmes

• Patient groups are key for the successful introduction of new vaccines:
  – Awareness
  – Education
  – Information / communication
  – Advocacy
EFPIA principles for partnership

Established with patient organisations to ensure that relationships take place in an ethical and transparent manner

Updated in 2006

1. Independence of patient groups
2. Partnerships based on mutual respect
3. No promotion of prescription-only medicine
4. Transparent partnerships
5. Broad funding of patient groups from multiple sources
Existing codes/guidelines

By industry:

• UK, Sweden, Denmark, Netherlands, Ireland

By patient groups:

• General principles
• Types of relationships/financial support
• Transparency, editorial independence, etc.
Why establishing a Code?

- To ensure consistent ethical industry behaviour across Europe
- To help meeting stakeholders’ expectations of transparency
- To contribute to successful relationships / partnership with patient groups
Scope of the EFPIA Code

- To define relationship between EFPIA members / subsidiaries / contracted third parties and patient organisations which operate in Europe

- **Patient organisations:** not-for-profit organisations (and umbrella organisations) composed of patients and/or caregivers that represent and/or support the needs of their members.
Provisions of the Code

8 Articles
1. Non-promotion of prescription medicines
2. Written agreements
3. Use of logos and proprietary materials
4. Editorial control
5. Transparency
6. Diversified funding
7. Reasonable hospitality
8. Enforcement

2 appendices
I. Template for written agreements
II. Implementation and procedure rules
Provisions of the Code

1. **Non-promotion of prescription-only medicines**
   - No advertising to the general public

2. **Written agreements with patient groups**
   - Ensuring clear role of industry & patient groups
   - Clear and simple document including
     - Purpose
     - Amount of direct funding
     - Indirect financial and non-financial support
   - Model template for written agreements
3. **Use of logos and proprietary material:**
   - Written permission for use of the patient organisation’s logos or materials

4. **Editorial control:**
   - No influence on editorial content to favour commercial interest (except corrections of factual inaccuracies)
5. **Transparency**

- Companies to make publicly available a list of sponsored patient groups once a year (incl. significant indirect/non-financial support) + description nature support (by end of Q1 2009)
- Sponsorship clearly acknowledged and apparent

6. **Diversified funding:**

- No company may require to be sole funder of patient group or any of its major programmes
Provisions of the Code

7. Events and hospitality
   - Must be held in an appropriate venue (avoid those “renowned” for their entertainment facilities)
   - Reasonable in level and secondary to the purpose of the event
   - Limited to travel, meals, accommodation and registration fees

8. Enforcement
   - Implementation and procedures rules provided in appendix of the Code
EFPIA Code of Practice

- Effective 1 July 2008 (latest)

- Applies to EFPIA member companies, their subsidiaries and contracted 3rd parties

- Applies also to members EVM and EBE

- EU patient groups consulted
Implementation of the EFPIA Code

- EFPIA member associations to implement the code at national level
- Establish national procedures and structures to receive and process complaint and sanctions
- Establish an EFPIA Code Surveillance Committee to assist and monitor member associations
Applicability of EFPIA Code

- **In all cases**: existing national code of country where company providing funds is located prevails
- **For partnerships at national level**: governed by national code of country where activity takes place
- **For cross-border partnership**: governed by national code of country of main European location of patient group
- **Most restrictive code provisions will apply**
Conclusion

• The pharmaceutical industry has many common interests with patient organisations

• This code is a necessary process to ensure transparency and effectiveness of partnerships

• It contributes to Human Rights in relation to Health and Access to Medicines
More information: www.efpia.eu

EFPIA’s Binding Ethical Standards

- The pharmaceutical industry has many interests in common with patient organisations, which represent and/or support the needs of patients and/or caregivers.
- By working with patient organisations, the pharmaceutical industry is better able to understand and address patient needs and concerns of research and medicines.
- Industry funding to patient organisations helps to support programmes that improve the lives of people with a wide range of medical conditions.

As of 1 July 2008, the EFPIA Code of Conduct on Relationships between the Pharmaceutical Industry and Patient Organisations will apply to all 1200 companies EFPIA represents directly and indirectly across Europe, including companies that are members of EFPIA’s specialised groups: EBE (European Biopharmaceutical Enterprises) and EVM (European Vaccines Manufacturers).

National authorities and procedures will be in place to process complaints and impose sanctions, in which non-industry stakeholders will be represented. Publication of the names of patient organisations supported by the pharmaceutical industry will take place no later than 1 April 2009. A review of the Code will be initiated after the first year of implementation.

Addresses
EFPIA
Lionel/Plaza-Building
Waultier/Thone 209 - 2nd Floor
B-1050 Brussels
Tel: +32 (0)2 662.25.71
E-mail: info@efpia.org
www.efpia.eu

Code of Practice

Our Commitment

- Non-promotion
  - EU and national legislation and codes of practice apply
- Clarity
  - Written agreements defining pharmaceutical companies’ support
- Use of Logos
  - Written permission for the use of logos or materials
- Editorial Control
  - No influence of editorial content to favor commercial interests
- Transparency
  - Information about who pharmaceutical companies support and how
- Diversified Funding
  - Encourage multiple sources of funding for patient organisations
- Reasonable Hospitality
  - Hospitality limited to a reasonable level

Relationships between the Pharmaceutical Industry and Patient Organisations